Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Fluorescence In Situ Hybridization Analysis Of Circulating Tumor Cells In Metastatic Prostate Cancer

M. Leversha, J. Han, Z. Asgari, D. Danila, O. Lin, Rita Gonzalez-Espinoza, A. Anand, H. Lilja, G. Heller, M. Fleisher, H. Scher
Published 2009 · Biology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Purpose: To assess the feasibility of characterizing gene copy number alteration by fluorescence in situ hybridization (FISH) of circulating tumor cells (CTC) isolated using the CellSearch system in patients with progressive castration-resistant metastatic prostate cancer. Experimental Design: We used probe combinations that included the androgen receptor (AR) and MYC genes for FISH analysis of CTC samples collected from 77 men with castration-resistant metastatic prostate cancer. Results: High-level chromosomal amplification of AR was detected in 38% and relative gain of MYC in 56% of samples analyzed. No such abnormalities were detected in samples with CTC counts of <10, reflecting ascertainment difficulty in these lower count samples. Conclusion: The CTC isolated from our patient cohort present a very similar molecular cytogenetic profile to that reported for late-stage tumors and show that FISH analysis of CTC can be a valuable, noninvasive surrogate for routine tumor profiling. That as many as 50% of these patients have substantial amplification of the AR locus indicates that androgen signaling continues to play an important role in late-stage prostate cancer.
This paper references
10.1016/S0268-960X(05)80023-2
Fluorescence in situ hybridization.
C. M. Price (1993)
Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant.
T. Fehm (2002)
10.1038/1911178A0
Distribution of Human Chromosome Counts in Relation to Age
P. A. Jacobs (1961)
10.1093/JNCI/91.18.1574
Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma.
K. Sato (1999)
Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma Imaging
R B Jenkins
Circulating tumor cells predict overall survival following treatment in metastatic prostate cancer
DeBonoJS (2008)
10.1038/NG0495-401
In vivo amplification of the androgen receptor gene and progression of human prostate cancer
T. Visakorpi (1995)
10.1002/path.1206
Amplification of the androgen receptor gene in bone metastases from hormone‐refractory prostate cancer
R. S. Brown (2002)
10.1002/(SICI)1096-9896(199709)183:1<51::AID-PATH1092>3.0.CO;2-N
Increased cell proliferation activity and decreased cell death are associated with the emergence of hormone‐refractory recurrent prostate cancer
P. Koivisto (1997)
10.1158/1078-0432.CCR-08-0872
Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
J. D. de Bono (2008)
10.1158/1078-0432.CCR-06-2701
Circulating Tumor Cell Analysis in Patients with Progressive Castration-Resistant Prostate Cancer
D. Shaffer (2007)
Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization.
R. Jenkins (1997)
10.1677/ERC.1.00525
Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer.
H. Scher (2004)
10.1056/NEJMOA040766
Circulating tumor cells, disease progression, and survival in metastatic breast cancer.
M. Cristofanilli (2004)
Cytogenetic analysis of Circulating Tumor Cells of metastatic prostate cancer
A. Tibbe (2008)
Phase I/II study ofMDV3100 in patients (pts) with progressive castration-resistant prostate cancer (CRPC)
HI Scher (2008)
10.1038/sj.bjc.6690825
Detection of circulating tumour cells in patients with breast or ovarian cancer by molecular cytogenetics
H. Engel (1999)
10.1016/S0002-9440(10)61126-1
Mapping and gene expression profile of the minimally overrepresented 8q24 region in prostate cancer.
N. Tsuchiya (2002)
Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping.
M. Cher (1996)
10.1200/JCO.2007.15.9749
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.
G. Attard (2008)
10.1002/gcc.10155
DNA microarrays for comparative genomic hybridization based on DOP‐PCR amplification of BAC and PAC clones
H. Fiegler (2003)
Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer.
P. Koivisto (1997)
10.1158/1078-0432.CCR-04-0378
Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases
W. Allard (2004)
Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays.
L. Bubendorf (1999)
10.1002/IJC.2910580212
Prognostic value of deoxyribonucleic acid content in prostate cancer: A review of current results
J. Adolfsson (1994)
10.1158/1078-0432.CCR-07-1506
Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer
D. Danila (2007)
10.1038/nrg1692
The new cytogenetics: blurring the boundaries with molecular biology
M. Speicher (2005)
10.1200/JCO.2008.26.15_SUPPL.5006
Phase I/II study of MDV3100 in patients (pts) with progressive castration-resistant prostate cancer (CRPC)
H. Scher (2008)
10.1016/J.HUMPATH.2006.09.008
Androgen receptor amplification is associated with increased cell proliferation in prostate cancer.
K. Haapala (2007)
10.1186/1476-4598-5-33
Comparison of chromosomal and array-based comparative genomic hybridization for the detection of genomic imbalances in primary prostate carcinomas
F. R. Ribeiro (2006)
10.1200/JCO.2007.12.4487
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
H. Scher (2008)
FISH analysis of gene aberrations (MYC, CCND1, ERBB2, RB, AR) in prostatic carcinomas before and after androgen deprivation therapy
C Kaltz-Wittmer (2000)
10.1200/JCO.2007.15.8923
Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer.
S. Cohen (2008)
10.1097/01.LAB.0000074889.76221.49
Genetic Evaluation of Localized Prostate Cancer in a Cohort of Forty Patients: Gain Of Distal 8q Discriminates Between Progressors and Nonprogressors
H. Dekken (2003)
10.1038/labinvest.3780152
FISH Analysis of Gene Aberrations (MYC, CCND1, ERBB2, RB, and AR) in Advanced Prostatic Carcinomas Before and After Androgen Deprivation Therapy
C. Kaltz-Wittmer (2000)



This paper is referenced by
10.1128/9781555818722.CH111
Circulating Tumor Cells as an Analytical Tool in the Management of Patients with Cancer
D. Danila (2016)
10.1158/1078-0432.CCR-16-3081
The Novel Association of Circulating Tumor Cells and Circulating Megakaryocytes with Prostate Cancer Prognosis
L. Xu (2017)
10.1007/s00432-011-0988-y
Circulating tumor cells: advances in detection methods, biological issues, and clinical relevance
Yun-fan Sun (2011)
Mechanisms of resistance to intermittent androgen deprivation in prostate cancer patients identified by a novel computational method
Jason D. Morken (2014)
10.1586/era.12.59
Current and emerging treatments in the management of castration-resistant prostate cancer
David Shapiro (2012)
10.1038/nrclinonc.2014.82
Circulating tumour cells—monitoring treatment response in prostate cancer
D. Miyamoto (2014)
10.1007/s10544-013-9784-6
Enrichment of prostate cancer cells from blood cells with a hybrid dielectrophoresis and immunocapture microfluidic system
C. Huang (2013)
10.1684/bdc.2012.1565
[Circulating tumor cells and advanced prostate cancer].
T. Murez (2012)
10.1146/annurev-chembioeng-060713-035958
A new toolbox for assessing single cells.
Konstantinos Tsioris (2014)
10.1158/0008-5472.CAN-13-2051
Molecular profiling of tumor cells in cerebrospinal fluid and matched primary tumors from metastatic breast cancer patients with leptomeningeal carcinomatosis.
M. Magbanua (2013)
10.3978/j.issn.1000-9604.2015.09.02
Notes for developing a molecular test for the full characterization of circulating tumor cells.
E. Rossi (2015)
10.1002/9781118311912.CH2
Gene Technology: Applications and Techniques
P. Bisen (2012)
10.3390/ijms140815615
Experimental Evidence of Persistent Androgen-Receptor-Dependency in Castration-Resistant Prostate Cancer
T. Kobayashi (2013)
10.3892/OL.2015.3114
Amplification and protein expression of androgen receptor gene in prostate cancer cells: Fluorescence in situ hybridization analysis.
X. Zhang (2015)
10.1016/j.ymeth.2012.05.005
The challenge of gene expression profiling in heterogeneous clinical samples.
F. Rodríguez-González (2013)
10.1007/s10555-013-9422-z
Dormancy in solid tumors: implications for prostate cancer
N. Ruppender (2013)
10.2478/PJVS-2013-0022
The application of circulating tumor cells detecting methods in veterinary oncology.
M. Chmielewska (2013)
10.18632/oncotarget.10396
Phenotypic and genetic heterogeneity of tumor tissue and circulating tumor cells in patients with metastatic castrationresistant prostate cancer: a report from the PETRUS prospective study
C. Massard (2016)
10.1155/2012/781459
Biomarker-Based Targeting of the Androgen-Androgen Receptor Axis in Advanced Prostate Cancer
M. Kohli (2012)
10.1016/j.drudis.2009.11.006
Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?
C. P. Carden (2010)
10.1002/pros.21196
Bipolar androgen therapy: The rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer
S. Denmeade (2010)
Targeting the PI 3 K / Akt / mTOR pathway in castration-resistant prostate cancer
R. Bitting (2013)
10.1586/eem.10.49
Molecular processes leading to aberrant androgen receptor signaling and castration resistance in prostate cancer
R. Hu (2010)
10.1097/PPO.0b013e31823e69ac
Circulating Tumors Cells as Biomarkers: Progress Toward Biomarker Qualification
D. Danila (2011)
10.1038/nrclinonc.2013.253
Molecular analysis of circulating tumour cells—biology and biomarkers
M. Krebs (2014)
10.1097/JTO.0b013e31823f125d
Prognostic Impact of Circulating Tumor Cells in Patients with Small Cell Lung Cancer
T. Naito (2012)
10.1002/elps.201300242
Characterization of a hybrid dielectrophoresis and immunocapture microfluidic system for cancer cell capture
C. Huang (2013)
10.1016/j.mce.2011.12.019
Androgen receptor (AR) aberrations in castration-resistant prostate cancer
K. Waltering (2012)
10.3390/diagnostics5040428
When Prostate Cancer Circulates in the Bloodstream
V. Vlaeminck-Guillem (2015)
10.1038/nrurol.2016.224
Circulating tumour cells as biomarkers of prostate, bladder, and kidney cancer
M. Gorin (2017)
10.1002/smll.201601394
Affinity Versus Label-Free Isolation of Circulating Tumor Cells: Who Wins?
Vasudha Murlidhar (2016)
10.1007/978-1-4471-2864-9_74
Hormone-Based Therapies for Castration-Resistant Prostate Cancer
E. Mostaghel (2013)
See more
Semantic Scholar Logo Some data provided by SemanticScholar